OptimizeRx (OPRX) Projected to Post Earnings on Tuesday

Key Points

• OptimizeRx will report Q1 2026 results after the market closes on Tuesday, May 12, with analysts projecting EPS of $0.01 and revenue of $18.353 million and a conference call at 4:30 PM ET.
• The Board authorized a $10.0 million share buyback (up to ~6.8% of outstanding shares), while institutional investors own roughly 76.47% of the stock, signaling confidence from large holders.
• Shares recently traded down to $6.59 (52‑week range $5.54–$22.25) with a market cap of ~$124M and a PE of 25.32; analysts have a "Moderate Buy" consensus and a consensus price target of $17.57.

OptimizeRx (NASDAQ:OPRX - Get Free Report) is expected to be posting its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect OptimizeRx to post earnings of $0.01 per share and revenue of $18.3530 million for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%. On average, analysts expect OptimizeRx to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

OptimizeRx Stock Down 2.7%

OptimizeRx stock traded down $0.18 during trading on Tuesday, reaching $6.59. The stock had a trading volume of 167,833 shares, compared to its average volume of 439,579. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.17. OptimizeRx has a 52-week low of $5.54 and a 52-week high of $22.25. The stock has a market cap of $123.61 million, a PE ratio of 25.32 and a beta of 1.19. The business has a 50 day moving average price of $6.74 and a 200 day moving average price of $11.50.

OptimizeRx announced that its Board of Directors has authorized a share buyback plan on Thursday, March 5th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its shares are undervalued.

Hedge Funds Weigh In On OptimizeRx

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in OptimizeRx by 15.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company's stock worth $21,712,000 after purchasing an additional 138,224 shares during the period. Kennedy Capital Management LLC increased its stake in OptimizeRx by 42.8% in the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company's stock valued at $13,836,000 after purchasing an additional 202,446 shares during the period. Parkman Healthcare Partners LLC increased its stake in OptimizeRx by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company's stock valued at $10,447,000 after purchasing an additional 2,188 shares during the period. State Street Corp increased its stake in OptimizeRx by 21.6% in the fourth quarter. State Street Corp now owns 477,531 shares of the company's stock valued at $5,855,000 after purchasing an additional 84,808 shares during the period. Finally, Manatuck Hill Partners LLC raised its holdings in shares of OptimizeRx by 3.8% in the third quarter. Manatuck Hill Partners LLC now owns 472,307 shares of the company's stock valued at $9,682,000 after buying an additional 17,307 shares during the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. B. Riley Financial reissued a "buy" rating and issued a $11.00 target price (down from $28.00) on shares of OptimizeRx in a report on Friday, March 6th. Roth Mkm cut their target price on OptimizeRx from $32.00 to $18.00 and set a "buy" rating on the stock in a research report on Friday, March 6th. Lake Street Capital dropped their price target on shares of OptimizeRx from $24.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, March 6th. Stephens cut their price objective on shares of OptimizeRx from $17.00 to $10.00 and set an "equal weight" rating on the stock in a report on Friday, March 6th. Finally, Stifel Nicolaus reduced their price objective on shares of OptimizeRx from $21.00 to $17.00 and set a "buy" rating for the company in a research report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, OptimizeRx currently has an average rating of "Moderate Buy" and a consensus price target of $17.57.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company's core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.